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Abstract
Background. Subthalamic deep brain stimulation (STN-DBS) is an effective treatment for selected Parkinson’s disease (PD)
patients. Gait characteristics are often altered after surgery, but quantitative therapeutic effects are poorly described. Objective.
The goal of this study was to systematically investigate modifications in asymmetry and dyscoordination of gait 6 months
postoperatively in patients with PD and compare the outcomes with preoperative baseline and to asymptomatic controls
without PD.Methods.A convenience sample of thirty-two patients with PD (19 with postural instability and gait disorder (PIGD)
type and 13 with tremor dominant disease) and 51 asymptomatic controls participated. Parkinson patients were tested prior to
the surgery in both OFF and ON medication states, and 6-months postoperatively in the ON stimulation condition. Movement
Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) I to IV and medication were compared to pre-
operative conditions. Asymmetry ratios, phase coordination index, and walking speed were assessed. Results. MDS-UPDRS I to
IV at 6 months improved significantly, and levodopa equivalent daily dosages significantly decreased. STN-DBS increased step
time asymmetry (hedges’ g effect sizes [95% confidence interval] between pre- and post-surgery: .27 [-.13, .73]) and phase
coordination index (.29 [-.08, .67]). These effects were higher in the PIGD subgroup than the tremor dominant (step time
asymmetry: .38 [-.06, .90] vs .09 [-.83, 1.0] and phase coordination index: .39 [-.04, .84] vs .13 [-.76, .96]). Conclusions. This study
provides objective evidence of how STN-DBS increases asymmetry and dyscoordination of gait in patients with PD and suggests
motor subtypes-associated differences in the treatment response.
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Introduction
Deep brain stimulation (DBS) that targets the subthalamic
nucleus (STN) of the basal ganglia has shown therapeutic
potential as an adjunct to pharmacotherapy for alleviating
motor symptoms of Parkinson’s disease (PD).1 While the
treatment appears effective in providing relief to the cardinal
motor deficiencies of the disease (bradykinesia/akinesia, tremor,
and rigidity), the outcomes on gait remain inconclusive.2,3
Evidence from long-term follow-up studies has shown that
certain aspects of gait function improve initially postoperatively
but then progressively worsen.4,5 It is estimated that gait de-
terioration occurs in about 25% of patients with PD (PwPD)
after subthalamic deep brain stimulation (STN-DBS)6 and a
subset of them may experience fall.7,8 The causes of insufficient
gait outcome are not well understood, and this is largely due to
the paucity of objective investigations of gait characteristics in
PwPD undergoing DBS.9
Most long-term studies have investigated gait outcomes
using Movement Disorder Society-Unified Parkinson’s Dis-
ease Rating Scale (MDS-UPDRS-III) clinical motor scores.10
Although MDS-UPDRS-III is an internationally accepted and
widely used clinical assessment scale (rapidly administered to
measure clinically relevant outcomes), it only includes very
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few evaluations on walking ability or gait. The subtleties in-
volved with controlling gait such as symmetry, variability, and
coordination are important but remain unevaluated in stan-
dardized MDS-UPDRS-III assessments. Moreover, such ob-
jective gait characteristics could be used as biomarkers for
reliable selection of DBS candidates,11 adaptive stimulation,12
and assessing treatment endpoints thereafter.13
One of the defining symptomatic gait characteristics of
PwPD is hypokinesia (slowness of walking) accompanied by
small and variable step length.14 The effects of STN-DBS on
walking speed and step length were investigated initially by
Allert and co-workers15 in a pre-post study (follow-up as-
sessments after 3 months) on 8 PwPD with severe disability.
They found a significant increase in step length as well as gait
velocity and subsequent studies have been able to corroborate
this finding in both ON–OFF stimulation as well as pre-post
designs.16-18 Previous evidence also suggests beneficial effect
of STN-DBS on hip, knee, and ankle joint range of
motions.11,16 However, varying reports on other important
gait parameters (e.g., cadence and dual limb support time) and
a general lack of long-term objective follow-ups preclude
concrete conclusions for the alleviation of gait deficits using
STN-DBS in PwPD.2,3,9
One pertinent investigation of STN-DBS in PwPD that has
not been adequately described is the effects on asymmetry and
dyscoordination of gait. This is particularly important because
asymmetrical gait characteristics are often the first motor
symptoms seen in these populations,19 demonstrated as a
clinical marker of prodromal PD20 and discriminate distinct
motor stages of PwPD.21 In clinics, the practice of using bi-
lateral DBS lead implantation is quite common, with surgical
targets and stimulation settings often optimized to achieve best
effects on upper limb tremor, rigidity etc., while minimizing
relevant adverse effects (can be referred to as ‘clinically de-
termined settings’, evaluated using MDS-UPDRS I to IV).
However, despite the prevalence of asymmetrical stimulation
settings for bilateral DBS, asymmetry, particularly in the lower
limbs has been shown to often persist15 or increase at 6 months
after surgery11 for unknown reasons. Importantly, insufficient
attention to asymmetry may be responsible for adverse events
including freezing of gait (FOG) and fall episodes in a sub-
group of patients after the surgery.22-24
As mobility and functional gait are critical for health and
quality of life, an in-depth account of stimulation to gait and
clinical outcome relations seems then essential for developing
a comprehensive DBS therapy in PwPD. The current study is
part of a larger research project designed to investigate the
predictive value of objective gait measures for DBS therapy
outcomes in PwPD. In an exploratory study design, we
systematically investigated alterations in our primary out-
come: MDS-UPDRS III and our secondary measures: gait
asymmetry, dyscoordination, and walking speed 6 months
post-DBS in PwPD. We tested the hypothesis that PD motor
subtypes, including tremor dominant (TD), postural insta-
bility and gait disorder (PIGD), and indeterminate (neither
tremor nor postural instability as defining features) types




A convenience sample of thirty-two PwPD (excluding drop-
outs, 26men, 6 women, withmean age 60.2 (SD 9.6) years, PD
duration: 10.3 (5.0) years, preoperative MDS-UPDRS-III in
OFF medication: 39.97 (12.51), and preoperative Hoehn and
Yahr scale in OFF medication: 2 (1–3) denotes mild or early
PD, Table 1 and Supplementary Table 1) were recruited at the
University Hospital of Zurich. In addition, 51 asymptomatic
controls without PD (22 men, 29 women, and mean age 66.6
(10.7) years) participated voluntarily (in response to flyers and
newspaper advertisements) in this study. Inclusion criteria for
the control participants consisted of the following: 40 to
90 years of age, free from neurological, psychiatric, and or-
thopedic disorders and were able to independently walk for
10 minutes. The study was approved (approval no: 2015-
00141) by Zurich Cantonal Ethics Commission and carried
out in accordance with the Declaration of Helsinki, the
guidelines of Good Clinical Practice, and the Swiss regu-
latory authority’s requirements. The subjects all provided
written, informed consent prior to participation. The de-
tailed surgical protocol and postoperative management of
patients are provided in Supplementary Methods 1. Stimu-
lation parameters are presented in Supplementary Table 2.
Data Collection
Clinical Assessment. Motor symptoms were assessed using
MDS-UPDRS III, evaluated twice pre-surgery—in the ON
and OFF medication conditions (as part of the levodopa
challenge test used to screen DBS candidates that demon-
strates levodopa responsiveness25)—as well as once around 6
months post-surgery in the medication and stimulation ON
condition. MDS-UPDRS I (non-motor symptoms), II (ac-
tivities of daily living), and IV (dyskinesias and motor
fluctuations) were also performed once (OFF medication
condition) before surgery and once after surgery. In addition,
dopaminergic treatment was recorded as levodopa equivalent
daily dose. The clinical subtypes of PwPD such as TD, PIGD,
and indeterminate types were also identified.26 The pre-
dominant symptom side was identified bymedical history and
during the clinical examination and substantiated using the
MDS-UPDRS asymmetry: difference between left and right
motor scores of MDS-UPDRS Part III (items 3.3–3.8 and
3.15–3.17).27
Objective Gait Measures. PwPD were tested prior to surgery in
the medication ON state, and once around 6 months after the
surgery in the ON medication and ON stimulation condition.
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Here, most subjects in the post-condition were still taking a
clinically adapted dose of medication (Supplementary
Methods 2), except for 3 subjects that were completely
OFF medication. The evaluators who performed the gait
analysis were not blinded to the group status (e.g., asymp-
tomatic controls vs PwPD). All participants were instructed to
walk (barefoot, self-selected speed, and without any aid or
assistance) continuously for 10 minutes in an eight-shape
around 2 marked spots 10 m apart. The use of an “8-walk”
protocol allows the collection of a high number of consec-
utive gait cycles during overground walking that is necessary
in order to reliably assess gait performance.28 A three-
dimensional motion capture camera system (10 cameras;
61 markers; 100 Hz; Vicon Nexus, version 2.3/2.8.2, Oxford
Metrics, United Kingdom) was used to record the move-
ments. Before each data collection, a calibration routine was
performed across the entire capture volume (calibration error
threshold set at 0.5 mm). In addition, we followed the
published recommendations for minimizing error associated
with marker placement.29 The trajectories of the heel (cal-
caneus), toe (metatarsal head III), and sacrum (midpoint
between left and right posterior superior iliac spines) markers
were used to extract gait kinematics.
Data Analyses
Pre-processing. The raw kinematic data (from 2 × 7-m straight
sections of the 8-walk) were low pass filtered (zero phase
fourth order Butterworth with cut-off frequency of 25 Hz).
The gait events (heel strikes and toe-offs) were automatically
extracted using a custom algorithm based on foot velocity.30
Asymmetry ratio. Spatiotemporal gait measures of step length,
step time, swing time, and stance time (Supplementary
Methods 2) were evaluated for each foot separately. All
outliers defined as intervals outside ±4 median absolute
deviation (MAD) away from the median were eliminated.
The number of outliers eliminated by this process across all
parameters and participant groups was 15 (maximum) out of
221 (average) walking steps. For each subject, we then de-
termined which foot had the larger vs smaller amplitude (e.g.,







Asymmetry ratio of zero percentage indicates perfect
symmetry.
Phase coordination index. Bilateral dyscoordination in left–
right stepping phase was analyzed using the phase coordi-
nation index (PCI,32 Supplementary Methods 2). Lower PCI
values reflect a more accurate and consistent left–right
stepping phase generation.
Walking speed was additionally evaluated for all
individuals.








Healthy Controls vs PwPD
Pre-DBS P-value
Age (years) 66.6 (10.7) 60.2 (9.6) 60.9 (9.7) < .01
Male/female 22/29 27/5 27/5 < .01
Weight (kg) 68.1 (12.2) 77.0 (13.7) 78.6 (11.7) < .01
Height (cm) 168.9 (8.8) 176.0 (6.8) 175.9 (6.7) < .01
Age of onset of disease (yr) - 49.9 (9.3) - -
Disease duration (yr) - 10.3 (5.0) - -
H&Y stage - 2 (1–3) 2 (1–2.5) -
MDS-UPDRS-based clinical subtypes - TD (N = 13)
PIGD (N = 19)
Indeterminate (N = 0)
- -









Values expressed as mean (standard deviation) or median (lower limit–higher limit).
Differences in age, weight, and height were assessed using t-tests. Difference in no of male/female participants was assessed using a chi-square test. Statistical
significance was determined at P < .01.; Abbreviations: MDS-UPDRS, Movement Disorder Society-Unified Parkinson’s Disease Rating Scale; PwPD, patients with
Parkinson’s disease; DBS, deep brain stimulation; H&Y, Hoehn and Yahr; TD, tremor dominant; PIGD, postural instability and gait disorder.
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Statistical Analyses
For the comparison of demographic characteristics, t-tests and
chi-square tests were performed. Significance was set at .01.
Clinical scores. Changes in the overall clinical scores were
computed as: [(Pre-surgery scores – Post-surgery scores)/Pre-
surgery scores] × 100%. The Wilcoxon signed-rank test was
used to determine difference between the scores. Significance
was set at P < .05. In addition, we tested whether the overall
differences met the criteria of clinical relevance set by the
minimal clinically important difference (MCID) thresholds
(Part I:2.64 points,33 Part II:3.05 points,33 Part III:3.25
points,34 and Part IV: .9 points35).
Changes to individual items (and composite of sub-items)
were computed as mean differences [95% confidence inter-
val]. The procedure for obtaining bootstrap confidence in-
terval36 is detailed in Supplementary Methods 3. These
changes are not tested for significance because of large
number of ties (no differences) in the data.
Gait characteristics. For the investigation of the neuro-
modulatory effects of DBS treatment on asymmetry and
dyscoordination, effect sizes (ES) (Hedges’ g36) with 95%
confidence interval CI (Supplementary Methods 3) were
calculated using bootstrap resampling. The 95% CI on the
effect size gives a measure of precision and confidence about
our estimate and is not sensitive to the distribution of ob-
servations or underlying populations.37 The rationale for
including a control group is to demonstrate the importance of
the direction of intervention effects (e.g., modification in
asymmetry with respect to physiological asymmetry ob-
served in asymptomatic controls without PD). The P-value of
the two-sided permutation t-test is reported in case of sig-
nificant differences (Supplementary Methods 3). Significance
was set at P < .05.
All analyses were conducted in MATLAB (v2019a, The
Mathworks Inc., USA) and R (version 1.2.5033, The R
Foundation for Statistical Computing, Austria).
Results
Patient and Demographic Data
The overall subject dropout rate was 13.5% (5 PwPD). One
participant dropped out before surgery and 4 participants dropped
out after surgery as presented in Supplementary Figure 1. There
were significant differences (P < .01) in the age, proportion of
male/female, height, and weight between PwPD and
asymptomatic controls. Conversely, the 2 PwPD subtypes
groups did not significantly differ in those characteristics.
Clinical Characteristics
MDS-UPDRS data were collected at a mean of 2.6 (SD 1.6)
and 5.7 (.7) months before and after surgery, respectively. In
the standardized evaluation of motor symptoms of the dis-
ease, MDS UPDRS-III score improved from a baseline
OFF medication value of 39.97 (12.5) by 58% at 6 months
after surgery (Table 2). In comparison to the baseline OFF
medication at 6 months, the scores for UPDRS-I improved
by 27% (range:100 to 89), those for UPDRS-II improved
by 46% (range: 0 to 90), and those for UPDRS-IV im-
proved by 70% (0 to 100). All these functional improve-
ments were significant (P < .001) and exceeded the MCID
thresholds. Postoperatively, the levodopa equivalent daily
dosage also reduced significantly (P < .001) from 1118.8
(511.55) mg at baseline to 365.31 (219.86) mg at 6 months
after surgery (Table 2).
A subgroup analysis was performed on MDS-UPDRS III
items that address clinical subtypes. The average MDS-
UPDRS TD/PIGD ratio for TD group was 3.28 (1.34) and
for PIGD group .33 (.29). The mean difference [95% CI]
between the groups was 2.95 [2.32, 3.79]. None of the study
participants belonged to the indeterminate subtype. The
composite scores for tremor improved by 3.91 [2.41, 5.47],
and those for posture and gait improved by 1.19 [.59, 2.38],
both near to 50% group-level improvement. MDS-UPDRS
Asymmetry: The difference between left and right MDS-
UPDRS III motor subscores was 2.29 (7.59) in PwPD, 4.23
(8.69) in the TD group and .89 (6.32) in the PIGD group.
Gait Characteristics PwPD
PwPD had higher asymmetry ratios (highest effect size
reported for step length asymmetry, ES [CI]: .56 [.06, 1.03],
P < .05) and higher PCI (.81 [.3, 1.26], P < .05) before
surgery compared to the asymptomatic control group
(Supplementary Table 3).
Increase in step time asymmetry (.27 [-.13, .73]) and PCI
(.29 [-.08, .67]) was observed post-surgery relative to pre-
surgical status in PwPD. Differences in all other gait char-
acteristics between pre- and post-surgery were negligible
(Table 3).
Gait Characteristics Clinical Subtypes
Between subtypes. The magnitude of difference between the
TD and PIGD subtypes was larger for PCI and walking speed
(both ES’s > .50) before surgery. The differences between the
subtypes increased post-surgery relative to pre-surgical status
in all the gait characteristics (notably step time asymmetry .40
[-.33, .97] to .69 [-.03, 1.33] and PCI .60 [-.10, 1.13] to .78
[.06, 1.35], P < .05) except walking speed (.55 [-1.27, 0.22]
to .32 [-.98, 0.40]), Table 4.
Within subtypes. Step time asymmetry (.38 [-.06, .90]) and
PCI (.39 [-.04, .84]) increased in the PIGD group following
surgery. Differences in all other gait characteristics within
subtypes, between pre- and post-surgery were negligible
(Table 4).
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In comparison to asymptomatic controls without PD, the
PIGD group registered significant differences (P < .05) in the
following gait characteristics: step length asymmetry (.67
[-1.35,-.06]), step time asymmetry (.62 [-1.23,-.03]), and
PCI (1.08 [-1.64,-.42]) before surgery; step length asym-
metry (.60 [-1.3, 0.01]), step time asymmetry (1.1 [-1.8,-
.42]), swing time asymmetry (.63 [-1.2,-.03]), stance time
asymmetry (.66 [-1.22,-.03]), and PCI (1.45 [-2.14,-
.75]) after surgery, Supplementary Table 3.
Discussion
Our exploratory study was designed to investigate the ther-
apeutic effects of STN-DBS on gait asymmetry, dyscoordi-
nation, and walking speed 6 months post-surgery in PwPD.
Our results revealed the following: (1) As anticipated, PwPD
showed significant clinical motor and non-motor im-
provement (MDS-UPDRS I through IV) after surgery,
together with a significant reduction in dopaminergic
medication. (2) STN-DBS induced increase in step time
asymmetry and dyscoordination at follow-up. (3) Group
differences in baseline (before surgery) gait characteristics
are critical to discretize treatment planning, as indicated by
higher level of asymmetry, dyscoordination, and slower
walking speed in PIGD patients compared to the TD group.
Six-month increase in step time asymmetry and dyscoor-
dination after surgery were higher in the PIGD group than
the TD group. Collectively, our study documents novel
aspects of functional differences in DBS treatment re-
sponse guided by different motor subtypes with an eye
toward their relevance as objective biomarkers for use in
clinical settings.








PwPD Pre-DBS OFF Med vs PwPD
Post-DBS ON Med*
Overall scores
MDS-UPDRS I 10.13 (4.32) - 6.34 (2.70) 26. 86 (36.50)†
MDS-UPDRS II 13.44 (4.65) - 7.38 (3.90) 46.09 (23.10)†
MDS-UPDRS III 39.97 (12.5) 19.3 (7.4) 16.5 (7.7) 57.53 (15.68)†
MDS-UPDRS IV 7 (3.30) - 1.81 (2.26) 70.02 (32.23)†
Levodopa equivalent daily dose
(mg/day)
- 1118.8 (511.55) 365.31 (219.86) 64.50 (19.79)†
Subscores and individual items
Sub-items 3.15a till 3.18, sum of
tremor (0–40)
7.56 (6.32) 2.06 (3.39) 3.65 (3.50) 3.91 [2.41, 5.47]
Sub-items 3.10 till 3.12, sum of
PIGD (0–12)
2.41 (2.23) 1.06 (.83) 1.16 (1.50) 1.19 [.59, 2.38]
2.10. Item tremor (0–4) 1.19 (.95) - .81 (.74) .38 [.13, .59]
2.12. Itemwalking and balance (0–4) 1.13 (.48) - .84 (.63) .28 [.13, .41]
2.13. Item freezing (0–4) .66 (.85) - .23 (.49) .44 [.13, .72]
3.10. Item gait (0–4) 1.38 (.70) .78 (.41) .68 (.53) .66 [.44, .97]
3.11. Item freezing (0–4) .41 (.82) .09 (.29) .23 (.61) .19 [-.03, .56]








PwPD Pre-DBS OFF Med vs
PwPD Post-DBS ON Med*
Characteristic TD PIGD TD PIGD TD PIGD TD PIGD






















.77 (.42) 1.26 (.96) .77 (.89) 1.50
(1.77)
.46 [-.31, .77] 1.68 [.79,
3.58]
Values expressed as mean (standard deviation).
*3 patients were in OFF medication state.
Change on MDS-UPDRS I to IV and levodopa equivalent daily dose are provided as mean (standard deviation) percentages. †P < .001; The P values reported
denote level of statistical significant difference.
Changes on subscores, individual items, clinical subtypes are provided as mean differences [confidence intervals].; Abbreviations: MDS-UPDRS, Movement
Disorder Society-Unified Parkinson’s Disease Rating Scale; PwPD,Patients with Parkinson’s disease; DBS, deep brain stimulation; TD, tremor dominant; PIGD,
postural instability and gait disorder.
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Mild asymmetry in the walking patterns of asymptomatic
healthy individuals is quite common and plausibly func-
tional.38 It is likely that such asymmetrical patterns during
walking persist as a result of the natural hemispheric func-
tional specificities in the relative contribution of lower limbs
to propulsion (facilitate forward progression) and braking
(facilitate postural stabilization).38,39 In PwPD, asymmetry
markedly increases and has been directly related to poor
walking ability40,41 and adverse episodes such as FOG and
falls.16,42,43 The underlying pathophysiology leading to these
deficits are multifactorial and have not yet been completely
understood. We may conceivably (albeit inconclusively)
attribute these deficits to a bilateral but asymmetric neuro-
degenerative process that is characteristic of PD (asymmet-
rical motor function may persist over the years despite
bilateral disease progression44). Patients with PD (PwPD)
also appear to have reduced corpus callosum function, which
interferes with the normal bilateral coordination of limb
movements during walking.45 Although, there is only a
marginal agreement on the underpinnings of asymmetrical
motor and gait symptoms in PwPD, such features are starting
to provide essential movement biomarkers to guide diagnosis
and treatment.19,21
DBS treatment seems like an ideal approach for improving
asymmetry and dyscoordination of walking as it provides the
opportunity to modify stimulation parameters for each
hemisphere independently. However, we observed that STN-
DBS increased gait asymmetry and dyscoordination, when
comparing pre vs post-surgery. Similar to our findings, one
recent study11 also reported increased gait asymmetry 6-
month post-DBS compared to preoperative assessment.
These results differ from a previous work that demonstrated a
significant improvement in gait asymmetry in response to
STN-DBS treatment.16 The difference in results can be at-
tributed primarily to the study design (Johnsen and colleagues
only presented postoperative DBS OFF vs ON gait outcomes
in OFF medication state). Postoperative microlesion effects
(e.g., some permanent lesion related to electrode insertion)
may introduce bias46 and does not allow us to equate and
compare the pre-DBS state (of our study) to OFF DBS state
(in Johnsen et al 2009). Also relevant, however, is the def-
inition of gait asymmetry (Johnsen and colleagues looked at
spatial distance between heel to projected center of mass16).
The increase in asymmetry and dyscoordination that we are
reporting is calculated based on temporal metrics (step time
asymmetry and PCI).
With specific interest to the observation of increased step
time asymmetry (and PCI) and negligible effects on step
length asymmetry, our study plausibly suggests a differential
effect of STN-DBS on the temporal deficit or a possible
adaptation of temporal characteristics to allow regulation of
spatial characteristics. This coincides with other studies
showing that STN-DBS increases walking speed in patients
by spatial (increasing step length) rather than temporal
changes (increasing cadence or step time).2,17 There is sur-
mounting evidence indicating that cortical centers are re-
sponsible for movement initiation, while “ongoing”
movements are steadily regulated via subcortical regions
within the basal ganglia and the brain stem.47,48 These regions
are responsible for providing internal cues to cortical and
subcortical regions, for example, the pre-motor and supple-
mentary motor area, accounting for the regulation of spatial
parameters.49 In this regard, it is possible that the regulation
of temporal parameters is not under the influence of cortico-
thalamo-basal ganglia circuitry.50 However, further research
is necessary to substantiate the notion that these parameters
(cadence and step length, but also asymmetry in step time and
length) may reflect distinct regulation but allow mutual
interactions.51
Gait impairments in PwPD, from the symptom onset to
their advanced stages, including response to treatments
(levodopa52 and DBS53), demonstrate patient as well as group
Table 3. Effect of Bilateral Stimulation of the Subthalamic Nucleus on Gait Characteristics.
Characteristic PwPD Pre-DBS PwPD Post-DBS Healthy Controls PwPD Pre-DBS vs PwPD Post-DBS
Asymmetry (%)
Step length 4.81 (4.19) 4.60 (3.50) 2.90 (2.69) .05 [-.38, 0.32]
Step time 2.79 (2.32) 3.48 (2.61) 1.93 (1.70) .27 [-.13, 0.73]
Swing time 3.35 (4.19) 3.76 (4.07) 2.36 (1.92) .10 [-.24, 0.49]
Stance time 2.06 (2.66) 2.36 (2.72) 1.48 (1.20) .11 [-.21, 0.51]
Dyscoordination (%)
PCI 3.06 (1.06) 3.42 (1.41) 2.29 (.82) .29 [-.08, 0.67]
Other gait measures
Walking Speed (cm/s) 117.09 (18.21) 119.11 (18.42) 120.95 (14.31) .11 [-.11, 0.36]
Values expressed as mean (standard deviation).
Changes are provided as Hedges’ g effect size [95% confidence interval]. That is to say, we can be 95% confident that the interval contains the true effect size.
If PwPD post-DBS registered larger magnitude of gait parameter in comparison to PwPD pre-DBS, the effect size is positive. Abbreviations: PCI, phase
coordination index; PwPD, patients with Parkinson’s disease; DBS, deep brain stimulation.
Please refer to Supplementary Table 3 for comparison against healthy controls.
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(TD vs PIGD) specific traits. In our study, the TD group had
comparatively less impaired gait to the overall group of
patients both before and after surgery. On the other hand,
PIGD patients demonstrated a more pronounced increase
(more than the longitudinal changes due to disease pro-
gression reported previously in PwPD54) in asymmetry and
dyscoordination compared to the TD group due to DBS,
consistent with a previous clinical investigation.53 Natural
prognosis (PIGD may naturally progress more quickly in
disease course55) and inadequate targeting of the STN sub
territories responsible for the manifestation of the PIGD
subtype56 likely underlie differences in treatment outcomes,
but future studies may shed light on these hypotheses.
Limitations
We note the following limitations in our study. First, the
demographic characteristics (age, sex distribution, height,
and weight) of the PwPD group were significantly different
from asymptomatic controls group, but we did not factor this
in the estimation of effect sizes in the present study. A better
approach would be to use a statistical test that includes them
as covariates; however, this may require large sample sizes
which remain to be explored in future analyses. Second, the lack
of information about fall history of the participants limited our
ability to answer the question whether asymmetric and dys-
coordinated gait is associated with increased fall risk after STN-
DBS in PwPD. Third, there were also limitations in the design of
the study (gait being a secondary outcome) that did not allow us
to replicate novel unilateral stimulation protocols suggested
toward improving gait asymmetry and dyscoordination in pa-
tients with Parkinson’s disease.23 Fourth, the non-randomized
and unblinded design might be another limitation of our study.
Last, the relatively small sample of female PwPD may have
limited our ability to confirm previous observations57,58 of
gender-related factors for STN-DBS outcomes in PwPD.
Conclusion
The present findings show the efficacy of DBS of the STN in
reducing motor symptoms and related clinical outcomes in
PwPD at 6 months after surgery. Despite clinical improve-
ment, STN-DBS treatment altered temporal asymmetry and
dyscoordination of walking. In particular, PIGD patients
demonstrated a more pronounced decline in these gait
characteristics compared to the TD group.
STN is a complex subcortical motor network and regulate
a myriad of motor features required in daily life of PwPD.59
Current approaches to STN-DBS therapy are based on an
inadequate assessment of such features and thus hinder
providing any definitive recommendations about the ther-
apy. Our study provides preliminary insights into the
mechanisms possibly regulating DBS outcomes for subtle,
yet important gait features like symmetry and coordination.













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Ravi et al. 7
randomized controlled trials prior to translating into clinical
rehabilitation settings.
Acknowledgments
The authors would like to thank all the subjects for participating in
the study and their families for the support provided.
Author Contributions
NKI, DKR, NBS, CRB, andWRTconceived and designed the study.
CRB, LS, and MU coordinated the recruitment, pre-surgery, and
post-surgery of the participants. DKR, MG, EB, and NKI coordi-
nated the gait measurements. DKR, MG, and EB analyzed the data.
DKR, NBS, and WRT drafted the manuscript. CRB provided
clinical content expertise while drafting and revising the manuscript.
LS provided critical opinion and revision of the manuscript as a
subject expert. All the authors reviewed and approved the manu-
script for submission. WRT is the guarantor.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect
to the research, authorship, and/or publication of this article.
Funding
The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: DKR was
supported by a PhD scholarship from the State Secretariat for
Education, Research, and Innovation Switzerland [grant number
2016.0463].
Data Availability
Please contact the corresponding author for requests regarding data
sharing and collaboration.
Ethics Approval
The study was approved (approval no: 2015-00141) by Zurich
Cantonal Ethics Commission and carried out in accordance with the
Declaration of Helsinki, the guidelines of Good Clinical Practice,
and the Swiss regulatory authority’s requirements. The subjects all
provided written, informed consent prior to participation.
ORCID iDs
Deepak K. Ravi  https://orcid.org/0000-0002-5015-8901
Michelle Gwerder  https://orcid.org/0000-0003-4484-9244
William R. Taylor  https://orcid.org/0000-0003-4060-4098
References
1. Krack P, Volkmann J, Tinkhauser G, Deuschl G. Deep brain
stimulation in movement disorders: from experimental sur-
gery to evidence-based therapy. Mov Disord;34(12):1795-1810.
2019.
2. Collomb-Clerc A, Welter ML. Effects of deep brain stimulation
on balance and gait in patients with Parkinson’s disease: a
systematic neurophysiological review. Neurophysiol Clin. 2015;
45(4-5):371-388.
3. Cossu G, Pau M. Subthalamic nucleus stimulation and gait in
parkinson’s disease: a not always fruitful relationship. Gait &
Posture. 2017;52:205-210.
4. van Nuenen BFL, Esselink RAJ, Munneke M, Speelman JD,
van Laar T, Bloem BR. Postoperative gait deterioration after
bilateral subthalamic nucleus stimulation in parkinson’s dis-
ease. Mov Disord. 2008;23(16):2404-2406.
5. Krack P, Batir A, Van Blercom N, et al. Five-year follow-up
of bilateral stimulation of the subthalamic nucleus in ad-
vanced parkinson’s disease. N Engl J Med. 2003;349(20):
1925-1934.
6. Yin Z, Cao Y, Zheng S, et al. Persistent adverse effects fol-
lowing different targets and periods after bilateral deep brain
stimulation in patients with parkinson’s disease. J Neurol Sci.
2018;393:116-127.
7. Okun MS, Gallo BV, Mandybur G, et al. Subthalamic deep
brain stimulation with a constant-current device in parkinson’s
disease: an open-label randomised controlled trial. Lancet
Neurol. 2012;11(2):140-149.
8. Odekerken VJ, van Laar T, Staal MJ, et al. Subthalamic nucleus
versus globus pallidus bilateral deep brain stimulation for
advanced parkinson’s disease (NSTAPS study): a randomised
controlled trial. Lancet Neurol. 2013;12(1):37-44.
9. Fasano A, Aquino CC, Krauss JK, Honey CR, Bloem BR.
Axial disability and deep brain stimulation in patients with
parkinson disease. Nat Rev Neurol. 2015;11(2):98-110.
10. Schlenstedt C, Shalash A, Muthuraman M, Falk D, Witt K,
Deuschl G. Effect of high-frequency subthalamic neuro-
stimulation on gait and freezing of gait in parkinson’s
disease: a systematic review and meta-analysis. Eur J
Neurol. 2017;24(1):18-26.
11. Cebi I, Scholten M, Gharabaghi A, Weiss D. Clinical and
kinematic correlates of favorable gait outcomes from sub-
thalamic stimulation. Front Neurol. 2020;11:212.
12. Canessa A, Palmisano C, Isaias IU, Mazzoni A. Gait-related
frequency modulation of beta oscillatory activity in the sub-
thalamic nucleus of parkinsonian patients. Brain Stimul. 2020;
13(6):1743-1752.
13. O’Day J, Syrkin-Nikolau J, Anidi C, Kidzinski L, Delp S, Bronte-
Stewart H. The turning and barrier course reveals gait parameters for
detecting freezing of gait and measuring the efficacy of deep brain
stimulation. PLoS One. 2020;15(4):e0231984.
14. Morris M, Iansek R, McGinley J, Matyas T, Huxham F. Three-
dimensional gait biomechanics in parkinson’s disease: evidence
for a centrally mediated amplitude regulation disorder. Mov
Disord. 2005;20(1):40-50.
15. Allert N, Volkmann J, Dotse S, Hefter H, Sturm V, Freund H-J.
Effects of bilateral pallidal or subthalamic stimulation on gait
in advanced parkinson’s disease. Mov Disord. 2001;16(6):
1076-1085.
16. Johnsen EL, Mogensen PH, Sunde NA, Ostergaard K. Im-
proved asymmetry of gait in parkinson’s disease with dbs: gait
and postural instability in parkinson’s disease treated with
8 Neurorehabilitation and Neural Repair 0(0)
bilateral deep brain stimulation in the subthalamic nucleus.
Movement Disord. 2009;24(4):590-597.
17. Hurt CP, Kuhman DJ, Guthrie BL, Lima CR, Wade M, Walker
HC. Walking speed reliably measures clinically significant
changes in gait by directional deep brain stimulation. Front
Hum Neurosci. 2020;14:618366.
18. Roper JA, Kang N, Ben J, Cauraugh JH, Okun MS, Hass CJ.
Deep brain stimulation improves gait velocity in parkinson’s
disease: a systematic review and meta-analysis. J Neurol. 2016;
263(6):1195-1203.
19. Mirelman A, Bonato P, Camicioli R, et al. Gait impairments in
parkinson’s disease. Lancet Neurol. 2019;18(7):697-708.
20. Del Din S, Elshehabi M, Galna B, et al. Gait analysis with
wearables predicts conversion to parkinson disease. Ann
Neurol. 2019;86(3):357-367.
21. Mirelman A, Ben Or Frank M, Melamed M, et al. Detecting
sensitive mobility features for parkinson’s disease stages via
machine learning. Mov Disord. 2021.
22. Lai E, BryantM, Luo P, et al. Risk of falls in parkinson’s disease
after deep brain stimulation. Neurology. 2013;80.
23. Fasano A, Herzog J, Seifert E, et al. Modulation of gait co-
ordination by subthalamic stimulation improves freezing of
gait. Movement Disord. 2011;26(5):844-851.
24. Waldvogel D, Baumann-Vogel H, Stieglitz L, Hanggi-Schickli
R, Baumann CR. Beware of deep water after subthalamic deep
brain stimulation. Neurology. 2020;94(1):39-41.
25. Saranza G, Lang AE. Levodopa challenge test: indications,
protocol, and guide. J Neurol. 2020;268(9):3135-3143.
26. Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley
BC. How to identify tremor dominant and postural instability/gait
difficulty groups with the movement disorder society unified
parkinson’s disease rating scale: comparison with the unified
parkinson’s disease rating scale. Movement Disord. 2013;28(5):
668-670.
27. Uitti RJ, Baba Y, Whaley NR, Wszolek ZK, Putzke JD.
Parkinson disease: handedness predicts asymmetry. Neurology.
2005;64(11):1925-1930.
28. König N, Singh NB, von Beckerath J, Janke L, Taylor WR. Is
gait variability reliable? An assessment of spatio-temporal
parameters of gait variability during continuous overground
walking. Gait & Posture. 2014;39(1):615-617.
29. Tsushima H, Morris ME, McGinley J. Test-retest reliability and
inter-tester reliability of kinematic data from a three-
dimensional gait analysis system. J Jpn Phys Ther Assoc.
2003;6(1):9-17.
30. O’Connor CM, Thorpe SK, O’Malley MJ, Vaughan CL. Au-
tomatic detection of gait events using kinematic data. Gait &
Posture. 2007;25(3):469-474.
31. Nanhoe-Mahabier W, Snijders AH, Delval A, et al. Walking
patterns in parkinson’s disease with and without freezing of
gait. Neuroscience. 2011;182:217-224.
32. Plotnik M, Giladi N, Hausdorff JM. A new measure for quan-
tifying the bilateral coordination of human gait: effects of aging
and parkinson’s disease. Exp Brain Res. 2007;181(4):561-570.
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